Oncology · 1 h ago
Epigenomic priming may precede chemotherapy resistance in ovarian cancer
A longitudinal study of frozen biopsies from 16 patients with high-grade serous ovarian cancer (HGSOC) found that tumor-cell states associated with later chemotherapy resistance were detectable before treatment. The findings link these states to H3K4me1 chromatin marks and suggest a potential framework for studying resistance from biopsy samples.
- Study profiled longitudinal biopsies from 16 patients with HGSOC.
- Resistance-associated tumor programs were detectable before chemotherapy.
- H3K4me1 was enriched in these programs at baseline.
- Clinical prediction utility has not been established.
Researchers used multimodal single-nucleus profiling to examine transcriptional programs and histone modifications in longitudinal frozen biopsies from 16 patients with HGSOC. They assessed how tumor-cell states changed during chemotherapy and whether features of resistant states were present before treatment.
Tumors contained a limited set of functional states that changed reproducibly during treatment. Proliferative and interferon-responsive states were depleted, while TNFα-associated and epithelial–mesenchymal transition–associated programs persisted or expanded. These resistant programs were broadly enriched for the histone mark H3K4me1 before treatment. Baseline tumor composition was associated with survival, and fibroblast remodeling accompanied malignant adaptation. The findings suggest that resistance-associated states may be epigenetically primed before chemotherapy. The study is based on 16 patients; the abstract does not report effect sizes or establish a clinically validated method for predicting resistance.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Cancer Discovery: H3K4me1-Mediated Epigenomic Priming of Chemoresistant Tumor States in Ovarian Cancer ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.